BPG is committed to discovery and dissemination of knowledge
JOURNAL HOME
  • Homepage
  • Online Submission
Number of total visits
30910004
Number of visits today
7956
Number of downloads
13442185
MEMBERSHIP
BPG JOURNALS
Cited by in F6Publishing
For: Rausch M, Rutz A, Allard PM, Delucinge-Vivier C, Docquier M, Dormond O, Wolfender JL, Nowak-Sliwinska P. Molecular and Functional Analysis of Sunitinib-Resistance Induction in Human Renal Cell Carcinoma Cells. Int J Mol Sci 2021;22:6467. [PMID: 34208775 DOI: 10.3390/ijms22126467] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Xie Y, Shangguan W, Chen Z, Zheng Z, Chen Y, Zhong Q, Zhang Y, Yang J, Zhu D, Xie W. Establishment of Sunitinib-Resistant Xenograft Model of Renal Cell Carcinoma and the Identification of Drug-Resistant Hub Genes and Pathways. DDDT 2021;Volume 15:5061-74. [DOI: 10.2147/dddt.s343718] [Reference Citation Analysis]
2 Rausch M, Rutz A, Allard PM, Delucinge-Vivier C, Docquier M, Dormond O, Dyson PJ, Wolfender JL, Nowak-Sliwinska P. Drug Repurposing to Identify a Synergistic High-Order Drug Combination to Treat Sunitinib-Resistant Renal Cell Carcinoma. Cancers (Basel) 2021;13:3978. [PMID: 34439134 DOI: 10.3390/cancers13163978] [Reference Citation Analysis]
3 Armesto M, Marquez M, Arestin M, Errarte P, Rubio A, Manterola L, López JI, Lawrie CH. Integrated mRNA and miRNA Transcriptomic Analyses Reveals Divergent Mechanisms of Sunitinib Resistance in Clear Cell Renal Cell Carcinoma (ccRCC). Cancers (Basel) 2021;13:4401. [PMID: 34503211 DOI: 10.3390/cancers13174401] [Reference Citation Analysis]
Write to the Help Desk
© 2004-2022 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345